msmnainar
★    

India,
2021-06-22 16:24
(1417 d 16:41 ago)

Posting: # 22426
Views: 3,611
 

 Randomization [General Sta­tis­tics]

Hello all,

Need your expert opinion on the following,

Will there be any issue in adopting 2:1 (Test:Reference) randomization method in biosimilarity (BE) studies?

Note: The 2:1 randomization is mainly due to transition arm.

Sundar. M
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2021-06-22 17:05
(1417 d 15:59 ago)

@ msmnainar
Posting: # 22427
Views: 2,865
 

 2:1 allocation

Hi Sundar,

welcome back to the forum!

❝ Will there be any issue in adopting 2:1 (Test:Reference) randomization method in biosimilarity (BE) studies?


You will loose some power compared to equally sized treatment arms. For an [image]-script see there. It gives for an assumed CV 40% and T/R-ratio 0.95 targeted at 80% power:

n = 130 (1:1 allocation)
  nT = nR = 65
  power = 0.8035
n = 132 (naïve 2:1 allocation)
  nT = 88, nR = 44
  power = 0.7618
n = 147 (2:1 allocation)
  nT = 98, nR = 49
  power = 0.8060

If we desire a 2:1 allocation and want to preserve power, we need 13% more subjects than for the 1:1 allocation.

❝ Note: The 2:1 randomization is mainly due to transition arm.


What do you mean by that?

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
msmnainar
★    

India,
2021-06-23 18:49
(1416 d 14:15 ago)

@ Helmut
Posting: # 22428
Views: 2,826
 

 2:1 allocation

Hi Helmut,

Thanks for your detailed explanation.

❝ ❝ Note: The 2:1 randomization is mainly due to transition arm.


❝ What do you mean by that?


Transition arm is in general re-randomization at certain week after efficacy evaluation (FDA requirement).

Basically, 1:1 randomization allocation would lead to a larger sample size for subjects transitioning from Reference to Test, which would allow for detecting differences in immunogenicity and safety.

Sundar. M
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
131 visitors (0 registered, 131 guests [including 11 identified bots]).
Forum time: 09:05 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5